Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?

Boston Scientific Corp (NYSE:BSX) is one of Goldman Sachs top healthcare stocks. On March 4, TD Cowen reiterated that Boston Scientific Corp (NYSE:BSX) stock’s year-to-date decline appears overdone in the market. The stance follows a fireside chat with the company, whereby management affirmed confidence in achieving overall guidance.

Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?

The company also reiterated its positive outlook for its pulsed-field ablation and Watchman products. The company delivering on its guidance is expected to ease investor concern and trigger a stock recovery. Boston Scientific has already delivered 19.9% revenue growth over the past 12 months, affirming operational momentum despite recent headwinds.

Amid the positive outlook, TD Cowen has reiterated a Buy rating on Boston Scientific (BSX) with a $100 price target. The bullish outlook comes on the heels of the company delivering solid fourth-quarter and full-year 2025 earnings. Revenue in the quarter rose 15.9% year over year as adjusted earnings per share totaled $0.80, above the consensus estimate of $0.78 and guidance of $0.79.

Boston Scientific Corp. (NYSE:BSX) is a global medical technology leader that develops, manufactures, and markets less-invasive medical devices used in interventional specialties, including cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products, such as stents, pacemakers, and imaging systems, are used by healthcare professionals worldwide to diagnose and treat various diseases.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.